bioAffinity Technologies, Inc. BIAF
develop noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry
and automated analysis informed by machine learning, a form of artificial intelligence (AI). Our first commercial diagnostic test,
CyPath® Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells,
that indicate a malignancy in the lung.
Last close
2.80
2026-10-23
Market cap
$22.7M
2026-06-30 share count
52-week range
2.80 - 80.70
Valuation FY2025 figures against the last close
P/S3.7x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-8.66
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $6.2M | $9.4M | $2.5M | $4.8K | — | — |
| Cost of revenue | — | — | — | $467 | — | — |
| Gross profit | — | — | — | $4.3K | — | — |
| R&D | $1.4M | $1.5M | $1.5M | $1.4M | $1.0M | — |
| SG&A | $9.9M | $9.9M | $6.8M | $2.5M | $1.1M | — |
| Total operating expenses | $16.7M | $18.3M | $10.5M | $4.0M | $2.2M | — |
| Operating income | -$10.6M | -$9.0M | -$8.0M | -$4.0M | -$2.2M | — |
| Interest expense | $44.4K | $92.5K | $37.1K | $2.5M | $1.0M | — |
| Pre-tax income | -$14.9M | -$9.0M | -$7.9M | -$8.2M | -$6.3M | — |
| Income tax | $44.0K | $11.7K | $21.0K | $2.5K | $1.9K | — |
| Net income | -$14.9M | -$9.0M | -$7.9M | -$8.2M | -$6.3M | — |
| EPS, basic | -8.66 | -22.50 | -0.91 | -1.81 | -2.36 | — |
| EPS, diluted | -8.66 | -22.50 | -0.91 | -1.81 | — | — |
| Shares, diluted (wtd. avg.) | 1.7M | 404,167 | 8.7M | 4.5M | 2.7M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $6.4M | $1.1M | $2.8M | $11.4M | $1.4M | — |
| Inventory | $53.5K | $27.6K | $18.5K | $5.5K | — | — |
| Total current assets | $7.6M | $2.7M | $4.0M | $12.0M | $1.4M | — |
| Property, plant and equipment | $265.6K | $375.4K | $458.6K | $214.4K | $4.6K | — |
| Goodwill | $1.4M | $1.4M | $1.4M | — | — | — |
| Other intangibles | $716.8K | $775.1K | $833.5K | — | — | — |
| Total assets | $11.0M | $6.5M | $8.2M | $12.2M | $1.5M | — |
| Accounts payable | $761.9K | $987.3K | $604.8K | $345.0K | $230.4K | — |
| Short-term debt | $127.5K | — | — | — | — | — |
| Total current liabilities | $2.9M | $3.1M | $2.2M | $1.1M | $13.0M | — |
| Total liabilities | $3.7M | $3.9M | $3.4M | $1.1M | $13.2M | — |
| Retained earnings | -$68.6M | -$53.6M | -$44.6M | -$36.7M | -$28.5M | — |
| Total equity | $7.3M | $2.6M | $4.9M | $11.0M | -$15.8M | -$15.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$9.3M | -$7.3M | -$6.0M | -$4.1M | -$2.0M | — |
| Depreciation and amortisation | $170.4K | $162.3K | $233.1K | $10.2K | — | — |
| Stock-based compensation | $671.5K | $989.7K | $748.8K | $248.6K | $43.0K | — |
| Capital expenditure | $60.6K | $79.1K | $22.9K | $220.0K | — | — |
| Investing cash flow | -$60.6K | -$79.1K | -$2.2M | -$220.0K | — | — |
| Financing cash flow | $14.7M | $5.6M | -$345.0K | $14.3M | $3.3M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-010143.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $4.8K | $2.5M | $9.4M | $6.2M |
| Gross profit | — | — | $4.3K | — | — | — |
| Net income | — | -$6.3M | -$8.2M | -$7.9M | -$9.0M | -$14.9M |
Recent filings and events
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Other event Item 8.01
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event Item 8.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Other event Item 8.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 8731
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| IQV | IQVIA HOLDINGS INC. | $46.63B | 35.6x | 5.9% |
| INCY | INCYTE CORP | $23.12B | 18.1x | 21.2% |
| MEDP | Medpace Holdings, Inc. | $18.68B | 43.8x | 20.0% |
| CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | $16.49B | — | -0.9% |
| ABSI | Absci Corp | $1.58B | — | -38.2% |
| OABI | OmniAb, Inc. | $677.5M | — | -29.3% |
| NRC | NRC HEALTH | $485.1M | 0.4x | -4.0% |
| ONMD | OneMedNet Corp | $279.2M | — | 111.4% |